

The frequency of silent brain infarcts in polycythaemia vera and essential thrombocytosis

Frekvence tichého mozkového infarktu při pravé polycytémii a esenciální trombocytóze

Abstract

Aim: Stroke or transient ischaemic attack in Ph chromosome-negative myeloproliferative neoplasms patients have been investigated many times, whereas there is limited research on silent brain infarcts. In our study, we explored the frequency of silent brain infarcts in a polycythaemia vera (PV) and essential thrombocytosis (ET) patient group and its relationship to disease-related factors. **Methods:** The study was designed retrospectively. PV and ET patients who were followed up between 2015–2021 were re-examined in terms of silent brain infarcts. There were 66 PV and ET patients who had an MRI scan of the brain. Nine patients were excluded due to symptomatic cerebrovascular disease, 25 were excluded due to having one or more of the following diseases or conditions: arterial hypertension, diabetes mellitus type 2, migraine, smoking, carotid stenosis. **Results:** JAK-2 (Janus Kinase-2) mutation was observed in 23 patients (67.6%) and silent cerebral ischaemia was detected in 22 patients (35.3%). The rate of JAK-2 mutation in patients with silent cerebral ischaemia was found to be statistically higher than those without ($P = 0.027$). The relationship between remission status and silent cerebral ischaemia was also found to be statistically significant, patients in the remission period having a lower rate of silent cerebral ischaemia ($P = 0.036$). **Conclusion:** The findings of mean age and silent cerebral infarction frequency support the theory that PV and ET are also risk factors of silent brain infarction and need to be screened during the follow-up term.

Souhrn

Cíle: U pacientů s myeloproliferativními neoplazmi negativními na Ph chromozom je často hodnocena CMP nebo tranzitorní ischemická ataka, ale výzkum týkající se tichých mozkových infarktů je omezený. V naší studii byla zkoumána frekvence tichých mozkových infarktů ve skupině pacientů s pravou polycytémií (polycytemia vera; PV) a esenciální trombocytózou (ET) a její souvislost s faktory souvisejícími s onemocněním. **Metody:** Jednalo se o retrospektivní studii. Pacienti s PV a ET, kteří byli sledováni v letech 2015–2021, byli znovu vyšetřeni na výskyt tichých mozkových infarktů. U 66 pacientů s PV a ET byla provedena MR mozku. Devět pacientů bylo vyloučeno z důvodu symptomatického cerebrovaskulárního onemocnění a 25 pacientů bylo vyloučeno z důvodu jednoho či více z následujících onemocnění či stavů: arteriální hypertenze, diabetes mellitus 2. typu, migréna, kouření, stenóza karotid. **Výsledky:** Mutace JAK-2 (Janusova kináza 2) byla pozorována u 23 pacientů (67,6 %) a tichá cerebrální ischemie byla zjištěna u 22 pacientů (35,3 %). Míra výskytu mutace JAK-2 u pacientů s tichou cerebrální ischemií byla statisticky významně vyšší než u pacientů bez ní ($p = 0,027$). Dále bylo shledáno, že existuje statisticky významný vztah také mezi remisí a tichou cerebrální ischemií. U pacientů v remisi bylo pozorováno méně tichých cerebrálních ischemií ($p = 0,036$). **Závěr:** Poznatky týkající se průměrného věku a četnosti tichých cerebrálních infarktů ukazují, že PV a ET jsou rizikovými faktory tichého mozkového infarktu a v průběhu dlouhodobého sledování je třeba provádět jejich screening.

The Editorial Board declares that the manuscript met the ICMJE "uniform requirements" for biomedical papers.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

**E. Karacıy¹, U. Ceník²,
A. Özşimşek¹, İ. Atalay Karacıy³,
Y. Yüksel⁴, V. Karacıy⁵, G. Kutlu⁶**

¹Neurology Department, ALKU Medicine Faculty, Alanya, Turkey

²Neurology Department, Training and Research Hospital, Muğla, Turkey

³Pathology Department, ALKU Training and Research Hospital, Alanya, Turkey

⁴Radiology Department, ALKU Medicine Faculty, Alanya, Turkey

⁵Hematology Department, ALKU Medicine Faculty, Alanya, Turkey

⁶Neurology Department, Sıtkı Koçman University Medicine Faculty, Muğla, Turkey



Ertan Karacıy, MD
Neurology Department
Alanya ALKU Medicine Faculty
Oba Mahallesi Fidanlık Caddesi
07400 Alanya/Antalya
Turkey
e-mail: ertan.karacıy1@hotmail.com

Accepted for review: 18. 3. 2021

Accepted for print: 12. 8. 2021

Key words

silent cerebral ischaemia – stroke – polycythaemia vera – essential thrombocytosis – JAK-2 mutation

Klíčová slova

tichá cerebrální ischemie – CMP – pravá polycytémie – esenciální trombocytóza – mutace JAK-2

Introduction

Myeloproliferative neoplasms (MPNs) are clonal stem cell-derived diseases [1]. In this study, we included patients who suffer from polycythaemia vera (PV) and essential thrombocytosis (ET), which are all subcategorized as Philadelphia (Ph) chromosome-negative classical MPNs. We evaluated silent brain infarcts in this patient group.

Thrombosis in this patient group is widespread. Detected thrombosis at or prior to the diagnosis of a MPN was estimated to be 34–38.6% in PV, 9.7–29.4% in ET [2]. The cumulative rate of thrombosis after diagnosis of MPN is estimated to be around 3% per patient-year in PV and ET [3]. Thrombotic events in MPNs patients may vary from mild microcirculatory disturbances to severe complications, myocardial infarction, ischaemic stroke, transient ischaemic attack (TIA), cerebral venous thrombosis or deep venous thrombosis [2].

Stroke and (TIA) are considered to be cerebrovascular diseases that often present with specific symptoms, nevertheless, neuropathological and imaging studies also show asymptomatic ischaemia as a kind of cerebrovascular disease [4]. Advancements in imaging techniques and widespread use of imaging tools have added a new dimension to the definition of cerebrovascular disease. These asymptomatic ischaemic areas are also defined as silent ischaemia or silent brain infarcts [5].

There are many studies on stroke or TIA in Ph chromosome-negative MPNs patients which have been investigated many times, whereas silent brain infarcts are under-researched. In our study we explored the frequency of silent brain infarcts in the PV and ET patient groups and its relationship to disease-related factors.

Methods

The study was designed retrospectively. Ph chromosome-negative MPNs patients (PV and ET) who were followed up at Muğla Sıtkı Kocman University Medical Faculty Hematology Clinic and Alanya Training and Research Hospital Hematology Clinic, Turkey between 2015–2021 were re-examined in terms of silent brain infarcts.

The World Health Organization (WHO) revised version of MPN diagnostic criteria from 2016 was used for the diagnostics of Ph chromosome-negative MPNs patients, the diagnoses of the patients dia-

Tab. 1. General characteristics of the patients.

N = 34	
age (years)	60.74 ± 12.59 (36–80)
sex	
male	22 (64.7)
female	12 (35.3)
follow-up period (months)	53 (1–240)
JAK-2 mutation	
yes	23 (67.6)
no	11 (32.4)
silent cerebral ischemia	
yes	22 (64.7)
no	12 (35.3)
antiplatelets	
no	7 (20.6)
acetylsalicylic acid	20 (58.8)
clopidogrel	7 (20.6)
primary disease treatment	
no	10 (29.4)
anagrelide	9 (26.5)
hydroxyurea	15 (44.1)
remission	
yes	14 (41.2)
no	20 (58.8)
MPN type	
polycythemia vera	16 (47.1)
essential thrombocytosis	18 (52.9)
hemoglobin (g/dL)	12.82 ± 2.53 (8.32–19.66)
platelets (103/μL)	438.21 ± 154.6 (178–727)

JAK-2 – Janus Kinase-2; MPN – myeloproliferative neoplasm Findings are shown with median ± standard deviation (min-max), median (min-max) or N (%) values.

gnosed before 2015 were checked and updated using 2016 diagnostic criteria. In PV, remission was defined as a haemoglobin value lower than 16 g/dL in women and 16.5 g/dL in men. ET remission was defined as a platelet value lower than 450×10³/μL. These are the basic remission criteria defined in WHO's revised MPN diagnostic criteria guideline.

There were 66 PV and ET patients who had a MRI scan of the brain. Nine patients were excluded due to symptomatic cerebrovascular disease, 25 were excluded due to having one or more of these diseases or conditions; arterial hypertension, diabetes mellitus type 2, migraine, smoking, carotid

stenosis. These are the main risk factors of silent brain infarcts. 34 out of 66 patients were included in the study.

T2-weighted MRI scans are used to identify silent brain infarcts and were supported with other sequences.

The data were analysed with the IBM SPSS 23.0 package program (IBM Corp., Armonk, NY, USA). Descriptive statistics are presented with N (%) and mean ± standard deviation (min-max) and median (min-max) values. The Pearson chi-square test and Fisher's Exact test were used in the analysis of the relationships between the categorical variables. The Shapiro-Wilk test was used in the analysis of normality assumption. For

the analysis of the difference between the measurement values of the two groups, the Mann-Whitney U test was used when the normal distribution was not fit, and Student's t test was used when it was fit. P values lower than 0.05 were considered statistically significant.

Results

General characteristics of the patients is presented in Tab. 1.

When the general characteristics of the patients were compared according to the presence of silent cerebral ischaemia, no difference was found in terms of the average age and sex distribution of the patients according to the presence of silent cerebral ischaemia. There was no significant difference between the mean follow-up periods of the group with silent cerebral ischaemia and the group without ($P = 0.631$) (Tab. 2).

The rate of *JAK-2* mutation was statistically significantly higher in patients with silent cerebral ischaemia than in patients without silent cerebral ischaemia (Tab. 2).

The relationship between remission status and silent cerebral ischaemia was found to be statistically significant. Accordingly, patients in the remission period had a lower rate of silent cerebral ischaemia ($P = 0.036$) (Tab. 2).

No significant difference was found in terms of antiplatelets usage, primer disease treatments, primary disease type, haemoglobin and platelet values according to the presence of silent cerebral ischaemia (Tab. 2).

Discussion

Thrombosis is a common complication of Ph chromosome-negative MPNs (PV and ET), especially in older patients [6]. Stroke is a well-known complication of Ph chromosome-negative MPNs. However, silent brain infarcts as a complication of Ph chromosome-negative MPNs have not been studied before. In our study, we estimated the frequency of silent brain infarcts in the Ph chromosome-negative MPNs patient group (PV and ET), and its relationship to disease-related factors. Silent brain infarcts are premises of disabling strokes, and screening these asymptomatic changes can reduce the risk of stroke and dementia with preventive therapies [5].

The prevalence of MRI-defined silent brain infarcts varies within the general population. The Helsinki Aging Brain Study (HABS) found the prevalence of silent infarction was 16%

Tab. 2. Comparison of the general characteristics of the patients and disease related factors according to the presence of silent cerebral ischemia.

	Silent cerebral ischemia (N = 22)	No silent cerebral ischemia (N = 12)	P value
age (years)	59.41 ± 12.41 (36–78)	63.17 ± 13.09 (39–80)	0.414
sex			
male	13 (59.1)	9 (75)	0.465
female	9 (40.9)	3 (25)	
follow-up period (months)	48 (1–150)	53 (1–240)	0.631
<i>JAK-2</i> mutation			
yes	10 (45.5)	1 (8.3)	0.027
no	12 (54.5)	11 (91.7)	
antiplatelets			
no	3 (13.6)	4 (33.3)	0.492
acetylsalicylic acid	14 (63.6)	6 (50)	
clopidogrel	5 (22.7)	2 (16.7)	
primary disease treatment			
no	7 (31.8)	3 (25)	0.903
anagrelide	6 (27.3)	3 (25)	
hydroxyurea	9 (40.9)	6 (50)	
remission			
yes	6 (27.3)	8 (66.7)	0.036
no	16 (72.7)	4 (33.3)	
MPN type			
polycythemia vera	10 (45.5)	6 (50)	0.8
essential thrombocythosis	12 (54.5)	6 (50)	
hemoglobin (g/dL)	13.02 ± 2.71 (8.78–19.66)	12.45 ± 2.21 (8.32–16.05)	0.54
platelets (103/μL)	408.5 (248–699)	530.5 (178–727)	0.363

Findings are shown with median ± standard deviation (min-max), median (min-max) or N (%) values. *JAK-2* – *Janus Kinase-2*; MPN – myeloproliferative neoplasm Student's t test, Mann-Whitney U test, Pearson ki-kare test, Fisher's Exact test were used for statistical analysis.

at the ages between 55 and 85 [7]. The Cardiovascular Health Study reported a 28% prevalence of silent brain infarction [8]. In the Austrian Stroke Prevention Study, their prevalence was 8% [9]. According to these studies, the prevalence of silent cerebral infarction in the general population is 8–28%. When we examined the selected groups with risk factors of stroke and silent ischaemia, the prevalence of silent cerebral infarction was found to be higher. In the review study by Vermeer et al, the frequency of silent cerebral infarction in patients with a mean age of 60 years and with coronary artery disease was 32%. Likewise, the frequency in patients with a mean age of 68 years and with atrial fibrillation was 32% [5]. According to Mathiesen

et al, in patients with a mean age of 68 years with asymptomatic carotid stenosis the silent cerebral infarction prevalence was 23% [10]. Studies on the silent cerebral infarction frequency in patients with arterial hypertension reported silent cerebral infarction frequency at around 43% [11–16]. Vermeer et al also report the MRI-defined silent cerebral infarction frequency as 38% in diabetes mellitus patients with a mean age of 62 years [5]. In the same review, the prevalence of MRI-defined silent cerebral infarction in a sickle cell patient group with a median age of 24 years was found to be 30%. In our study, we found a 35.3% prevalence of MRI-based silent cerebral ischaemia. The patients' mean age was 60.74 years (36–80).

Age is one of the main risk factors of silent cerebral infarction [17–19]. The mean age of the patients in our study was mostly similar to the risk groups mentioned above. The findings of mean age and silent cerebral infarction frequency support the theory that Ph chromosome-negative classical MPNs (PV and ET) are also risk factors of silent brain infarction and need to be screened during the follow-up term.

The presence of the *JAK-2* mutation in Ph chromosome-negative MPNs diseases is associated with thrombosis [20]. Weston et al examined thrombosis in ET patients and stated that there was a trend toward increased rates of prior thrombosis among *JAK2*-positive patients (27 vs. 5%) [21]. Larsen et al evaluated an ET cohort for possible clinical correlations to the *JAK2* mutation status including a history of previous thrombosis and reported a significant increase in the prevalence of arterial thrombosis in *JAK2*-positive ET patients ($P = 0.001$) [22]. In our study, the *JAK-2* mutation was observed in 67.6% of the patients and the rate of *JAK-2* mutation in patients with silent cerebral ischaemia was statistically significantly higher than those without it ($P = 0.027$).

Increased blood viscosity and increased platelet activation are risk factors of thromboembolism in PV and ET [23,24]. In our study, remission status was also statistically significantly related to the occurrence of silent cerebral ischaemia, patients in the remission period had a lower rate of silent cerebral ischaemia ($P = 0.036$). We assessed remission with parameters of complete blood count parameters but better assessment of *JAK-2* gene positive patients' remission is performing molecular genetic detection of *JAK-2* gene.

In our cohort, 7 patients (20.6%) were not using antiplatelets, 20 patients (58.8%) were using acetylsalicylic acid and 7 patients (20.6%) were using clopidogrel. No significant difference was found in terms of antiplatelets usage in patients with versus those without silent cerebral ischaemia. Low rates of silent brain ischaemia are expected in patients using antiplatelets according to stroke prevention procedures [25]

Hasson et al reported that hydroxurea prevented silent stroke in sickle cell disease [26]. In our study, 29.4% of patients did not receive treatment for their primary disease, 26.5% received anagrelide and 44.1% received hydroxyurea treatment. 20 patients

(58.8%) were in remission. No significant difference was found in terms of primary disease treatments and silent brain ischaemia. We assume that this is related to the low number of patients using disease treatments.

Our study has some limitations. First of all, it is a retrospective study. Future studies can be designed prospectively. Second, we evaluated mainly ET and PV patients. Future work could include primary myelofibrosis patients. Third, the sample size of the study should be increased. A larger sample size can capture the disease related factors and silent cerebral ischaemia more accurately.

Conclusion

Early diagnosis of silent cerebral ischaemia helps to prevent symptomatic strokes, even against large vessel occlusion which may cause serious disabilities, and dementia. It gives us time to take precautions. Ph chromosome-negative MPNs (PV and ET) are also a group of diseases that can be evaluated as a risk factor for cerebral silent ischaemia as shown in this study. We need prospective and larger sample sized studies to gain more detailed information about the relationship between silent cerebral ischaemia and Ph chromosome-negative MPNs.

Ethical principles

The entire study was conducted in accordance with the Helsinki Declaration of 1975 (as revised in 2004 and 2008). Ethics committee approval was obtained from the Alanya Alaattin Keykubat University Ethics Committee.

Conflict of interest

The authors declare they have no potential conflicts of interest concerning drugs, products or services used in the study.

References

1. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. *Blood* 2013; 22(13): 2176–2184. doi: 10.1182/blood-2013-03-460154.
2. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and *JAK2V617F*. *Semin Thromb Hemost* 2007; 33(4): 313–320. doi: 10.1055/s-2007-976165.
3. McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. *Semin Thromb Hemost* 2013; 39(1): 101–111. doi: 10.1055/s-0032-1331153.
4. Fisher CM. Lacunes: small, deep cerebral infarcts. *Neurology* 1965; 15: 774–784. doi: 10.1212/wnl.15.8.774.
5. Vermeer SE, Longstreth WT, Koudstaal PJ. Silent brain infarcts: a systematic review. *Lancet Neurol* 2007; 6(7): 611–619. doi: 10.1016/S1474-4422(07)70170-9.

6. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. *Br J Haematol*. 128(3): 275–290. doi: 10.1111/j.1365-2141.2004.05277.x.
7. Ylikoski A, Erkinjuntti T, Raininko R et al. White matter hyperintensities on MRI in the neurologically non-diseased elderly: analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. *Stroke* 1995; 26(7): 1171–1177. doi: 10.1161/01.str.26.7.1171.
8. Price TR, Manolio TA, Kronmal RA et al. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults. *Stroke* 1997; 28(6): 1158–1164. doi: 10.1161/01.str.28.6.1158.
9. Schmidt R, Schmidt H, Pichler M et al. C-reactive protein, carotid atherosclerosis, and cerebral small-vessel disease. Results of the Austrian Stroke Prevention Study. *Stroke* 2006; 37(12): 2910–2916. doi: 10.1161/01.STR.0000248768.40043.f9.
10. Mathiesen EB, Waterloo K, Joakimsen O et al. Reduced neuropsychological test performance in asymptomatic carotid stenosis: the Tromsø study. *Neurology* 2004; 62(5): 695–701. doi: 10.1212/01.wnl.0000113759.80877.1f.
11. Hougaku H, Matsumoto M, Kitagawa K et al. Silent cerebral infarction as a form of hypertensive target organ damage in the brain. *Hypertension* 1992; 20(6): 816–820. doi: 10.1161/01.hyp.20.6.816.
12. Kamide K, Raguki H, Nakano N et al. Insulin resistance is related to silent cerebral infarction in patients with essential hypertension. *Am J Hypertens* 1997; 10(11): 1245–1249. doi: 10.1016/s0895-7061(97)00282-3.
13. Sugiyama T, Lee JD, Shimizu H et al. Influence of treated blood pressure on progression of silent cerebral infarction. *J Hypertens* 1999; 17(5): 679–684. doi: 10.1097/00004872-199917050-00012.
14. Kario K, Pickering TG, Hoshida S et al. Morning blood pressure surge and hypertensive cerebrovascular disease: role of the α -adrenergic sympathetic nervous system. *Am J Hypertens* 2004; 17(8): 668–675. doi: 10.1016/j.amjhyper.2004.04.001.
15. Kario K, Pickering TG, Umeda Y et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. *Circulation* 2003; 107(10): 1401–1406. doi: 10.1161/01.cir.0000056521.67546.aa.
16. Kato T, Inoue T, Yamagishi S et al. Low-density lipoprotein subfractions and the prevalence of silent lacunar infarction in subjects with essential hypertension. *Hypertens Res* 2006; 29(5): 303–307. doi: 10.1291/hypres.29.303.
17. Longstreth WT Jr, Bernick C, Manolio TA et al. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. *Arch Neurol* 1998; 55(9): 1217–1225. doi: 10.1001/archneur.55.9.1217.
18. Vermeer SE, den Heijer T, Koudstaal PJ et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan study. *Stroke* 2003; 34(2): 392–396. doi: 10.1161/01.str.0000052631.98405.15.
19. Morrison AC, Fornage M, Liao D et al. Parental history of stroke predicts subclinical but not clinical stroke: the Atherosclerosis Risk in Communities Study. *Stroke* 2000; 31(9): 2098–2102. doi: 10.1161/01.str.31.9.2098.
20. Zerjavic K, Zagradisnik B, Stangler Herodez S et al. Is the *JAK2 V617F* mutation a hallmark for different forms of thrombosis? *Acta Haematol* 2010; 124(1): 49–56. doi: 10.1159/000314645.
21. Weston H, Bird R, Griffiths V et al. *JAK2 V617F* Mutation status predicts thrombotic complications, including

arterial thrombosis, in patients with essential thrombocytosis (ET). *Blood* 2007; 110(11): 2551. doi: 10.1182/blood.V110.11.2551.2551.

22. Larsen TS, Pallisgaard N, Møller MB et al. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: Independence of the V617F allele burden. *Hematology* 2008; 13(2): 71–76. doi: 10.1179/102453308X315960.

23. Lowe GD, Fowkes FG, Dawes J et al. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. *Circulation* 1993; 87(6): 1915–1920. doi: 10.1161/01.cir.87.6.1915.

24. Gori T. Viscosity, platelet activation, and hematocrit: progress in understanding their relationship with clinical

and subclinical vascular disease. *Clin Hemorheol Microcirc* 2011; 49(1–4): 37–42. doi: 10.3233/CH-2011-1455.

25. Ezekowitz MD. Prevention of stroke. *Am J Geriatr Cardiol* 1998; 7(5): 42–46.

26. Hasson C, Veling L, Rico J et al. The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis. *Medicine (Baltimore)* 2019; 98(51): e18225. doi: 10.1097/MD.000000000018225.

Care Comm s.r.o.

KOMUNIKACE ZDRAVOTNICKÝCH TÉMAT
JE NAŠE SRDEČNÍ ZÁLEŽITOST



publikační činnost:
odborné knihy
a časopisy pro lékaře
a specialisty



webové portály
se zdravotnickou
tematikou




kompletní servis
při natáčení
videorozhovorů
a on-line kongresového
zpravodajství



originální kongresové
zpravodajství



pořádání tiskových
konferencí
nebo kulatých stolů



Care Comm
we care...

V případě zájmu se na nás
neváhejte obrátit:
www.carecomm.cz
info@carecomm.cz